Skip to content

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04772469
Enrollment
934
Registered
2021-02-26
Start date
2021-03-22
Completion date
2023-04-26
Last updated
2025-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Immunodeficiency Syndrome, HIV Infections, Human Immunodeficiency Virus, Retroviridae Infections, RNA Virus Infections, Sexually Transmitted Diseases, Viral, Virus Diseases, Virus-HIV

Keywords

HIV/AIDS, Social Networks, Behavioral Economics, Incentives, PrEP, HIV Self-Testing, Fishermen, Sub Saharan Africa, Men, HIV Prevention

Brief summary

This is a randomized controlled trial to test a combination behavioral and biomedical interventions to improve the HIV prevention and care cascades in a population of mobile men in a high priority setting (fishermen in Kenya). The intervention strategy is to recruit and train highly socially-connected men to distribute HIV self-tests and provide linkage support to men in their close social networks. The study will determine whether this social network-based approach along with small financial incentives in the form of transport vouchers can increase men's self-testing, linkage to and uptake of ART and PrEP after self-testing, virologic suppression at 6 months (for those initiating ART) and PrEP adherence (for those initiating PrEP) at 6 months. The study includes a longitudinal qualitative and mixed methods (quantitative and qualitative assessments) to identify the pathways of intervention action, and understand how the social network-based approach with support for linkage affects testing and ART and PrEP uptake and retention in men.

Detailed description

In Aim 1, following the study pilot, community selection, and preparation the investigators will conduct a census/BMU registry verification in study communities to identify the population of men eligible for the study. The study will screen, recruit and enroll eligible men who give their informed consent to participate, then measure their close social networks identify network-central, highly-connected men (promoters) and randomize their close social network (a cluster) to 1:1 intervention and control groups. Investigators will then conduct a baseline survey to collect socio demographic and baseline sexual behavior data among men in the close social networks. Following this baseline data collection, all promoters will be provided a training. Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration. Promoters in the control group will receive basic HIV education and training about the study, and will be given vouchers that can be exchanged for HIV tests (standard or free HIVST kits) at nearby health facilities. Using follow-up survey data, investigators will test the hypothesis that a higher rate of HIV testing will be observed after 3 months among men in networks that receive the intervention compared to control. In Aim 2, investigators will test whether network-central promoters can enhance linkage to ART and PrEP after HIV testing among men in their close social networks. Promoters in the Aim 1 intervention group will be asked to distribute information and transport vouchers for ART or PrEP when distributing HIV self-tests to men in their close social networks. Investigators will use clinic data to test the primary hypothesis that the intervention will result in higher rates of linkage to ART or PrEP (confirmatory testing and ART referral for positives, and PrEP screening for negatives). Investigators also will test the hypothesis that higher ART and PrEP uptake will be observed within 3 months (+ about one month) in the intervention group. In Aim 3, investigators will measure 6 month VL and 6 month tenofovir levels using viral load testing and a novel point of care PrEP adherence assay (an antibody-based assay permitting measurement of tenofovir levels in urine) in study sites, and test the hypothesis that higher rates of virologic suppression will be observed in HIV-infected men, and PrEP adherence in un-infected men, in the intervention group. Viral load measurements will be conducted by drawing additional venous blood during routine blood draws scheduled for MOH viral load monitoring (as well as additional draws during scheduled appointments for those occurring outside of the annual VL testing standard of care window). PrEP adherence will be measured utilizing the study urine assay at 6 months. HIV treatment adherence will measured through adherence assessment during 3 and 6 routine clinic visits. Across all aims, investigators will assess the pathways of intervention action using qualitative and mixed methods. Investigators will identify the mechanisms of action, and barriers and facilitators of the social network and incentives intervention implementation, using qualitative and mixed methods quantitative and qualitative assessments embedded in Aims 1, 2 and 3. The data collection approach will include in-depth interviews with participants in both groups, key informant interviews with network-central promoters, and focus group discussions with study participants stratified by HIV status and study group. Data will be collected at baseline and three follow-up periods corresponding to the timing of quantitative outcome measurements in Aims 1 through 3.

Interventions

Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.

OTHERSmall monetary incentives

Use of small incentive voucher (\ $5) to encourage linkage to confirmatory testing.

BEHAVIORALUse of SMS/text reminders to motivate adherence to ART or PrEP

Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support.

Sponsors

University of Pennsylvania
CollaboratorOTHER
Impact Research & Development Organization
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
Duke University
CollaboratorOTHER
Kenya Medical Research Institute
CollaboratorOTHER
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

The study design is a cluster randomized controlled trial where the unit of randomization will be a clusters of men's close social network in study communities.

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult (18 years or older) * Male * Working as a fisherman or fishing-related occupation * Willing and able to provide informed consent for participation * Not participating in another research study related to HIV testing, treatment and/or prevention

Exclusion criteria

* Younger than 18 years of age * Female * Included in another intervention study on HIV/AIDS * Inadequate cognitive and/or hearing capacity to complete planned study procedures, at the discretion of the study team

Design outcomes

Primary

MeasureTime frameDescription
Self-reported HIV TestingUp to 3 monthsPercentage of participants who self-report HIV testing (yes/no) within the past 3 months, measured at 3-month follow-up.
Percentage of Participants Who Linked to a Study-affiliated Clinic Within 3 MonthsUp to 3 monthsThe percentage of participants who attended a study-affiliated clinic for HIV treatment or care within 3 months of the intervention baseline

Secondary

MeasureTime frameDescription
Linkage to PrEPUp to 3 monthsPercentage of PrEP-eligible HIV-negative participants who initiate PrEP prescription (yes/no), 3-months following confirmatory testing and eligibility screening (combined)
Adherence to PrEP (% With Detectable Tenofovir in the Urine)Up to 6 monthsPrEP: Percentage of PrEP-taking HIV-negative participants who are adherent to PrEP (TFV levels of \>= 1500 ng/mL) at 6 months following PrEP initiation.
Adherence to ARTUp to 6 monthsART: Percentage of HIV-positive participants who attain viral suppression (HIV RNA \<400 c/mL), 6 months following ART initiation.

Countries

Kenya

Participant flow

Pre-assignment details

Between June 2021 and March 2022, we enumerated 1,509 fishermen in three beach communities. Among these fishermen, 934 were mapped to social networks and comprised the intent-to-treat sample. Of these, 733 men were reached and completed a baseline survey.

Participants by arm

ArmCount
Intervention: Promoter Training, Multiple HIV Self-test Kit Distribution, and Incentive Distribution
Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks. Provision of multiple self-tests: Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks. Small monetary incentives: Use of small incentive voucher (\ $5) to encourage linkage to confirmatory testing. Use of SMS/text reminders to motivate adherence to ART or PrEP: Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support.
374
Intervention: Promoter Training, Multiple HIV Self-test Kit Distribution, and Incentive Distribution
Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks. Provision of multiple self-tests: Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks. Small monetary incentives: Use of small incentive voucher (\ $5) to encourage linkage to confirmatory testing. Use of SMS/text reminders to motivate adherence to ART or PrEP: Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support.
76
Control: Promoter Training and Referral for Testing
Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available.
359
Control: Promoter Training and Referral for Testing
Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available.
79
Total888

Baseline characteristics

CharacteristicControl: Promoter Training and Referral for TestingTotalIntervention: Promoter Training, Multiple HIV Self-test Kit Distribution, and Incentive Distribution
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
7 Participants15 Participants8 Participants
Age, Categorical
Between 18 and 65 years
352 Participants718 Participants366 Participants
Age, Continuous37.2 Years35.5 Years34.5 Years
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
359 Participants733 Participants374 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
Kenya
359 Participants733 Participants374 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
359 Participants733 Participants374 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
14 / 3740 / 359
other
Total, other adverse events
1 / 3740 / 359
serious
Total, serious adverse events
14 / 3740 / 359

Outcome results

Primary

Percentage of Participants Who Linked to a Study-affiliated Clinic Within 3 Months

The percentage of participants who attended a study-affiliated clinic for HIV treatment or care within 3 months of the intervention baseline

Time frame: Up to 3 months

ArmMeasureValue (NUMBER)
Promoter Training, Multiple Self-test Kits, and IncentivesPercentage of Participants Who Linked to a Study-affiliated Clinic Within 3 Months67.3 percentage of participants
Short Training and Referral for TestingPercentage of Participants Who Linked to a Study-affiliated Clinic Within 3 Months15.6 percentage of participants
Primary

Self-reported HIV Testing

Percentage of participants who self-report HIV testing (yes/no) within the past 3 months, measured at 3-month follow-up.

Time frame: Up to 3 months

Population: We used cluster adjusted means

ArmMeasureValue (NUMBER)
Promoter Training, Multiple Self-test Kits, and IncentivesSelf-reported HIV Testing65.6 percentage of participants
Short Training and Referral for TestingSelf-reported HIV Testing31.3 percentage of participants
Secondary

Adherence to ART

ART: Percentage of HIV-positive participants who attain viral suppression (HIV RNA \<400 c/mL), 6 months following ART initiation.

Time frame: Up to 6 months

ArmMeasureValue (NUMBER)
Promoter Training, Multiple Self-test Kits, and IncentivesAdherence to ART35.7 percentage of participants
Short Training and Referral for TestingAdherence to ART40.2 percentage of participants
Secondary

Adherence to PrEP (% With Detectable Tenofovir in the Urine)

PrEP: Percentage of PrEP-taking HIV-negative participants who are adherent to PrEP (TFV levels of \>= 1500 ng/mL) at 6 months following PrEP initiation.

Time frame: Up to 6 months

ArmMeasureValue (NUMBER)
Promoter Training, Multiple Self-test Kits, and IncentivesAdherence to PrEP (% With Detectable Tenofovir in the Urine)18.7 percentage of participants
Short Training and Referral for TestingAdherence to PrEP (% With Detectable Tenofovir in the Urine)8.3 percentage of participants
Secondary

Linkage to PrEP

Percentage of PrEP-eligible HIV-negative participants who initiate PrEP prescription (yes/no), 3-months following confirmatory testing and eligibility screening (combined)

Time frame: Up to 3 months

Population: We used cluster adjusted means, thus the value does not yield a whole number of participants.

ArmMeasureValue (NUMBER)
Promoter Training, Multiple Self-test Kits, and IncentivesLinkage to PrEP19.7 percentage
Short Training and Referral for TestingLinkage to PrEP19.6 percentage

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026